论文部分内容阅读
为观察ＥＡＰ方案治疗晚期胃癌的疗效和不良反应，采用ＥＡＰ方案（足叶乙甙、阿霉素或表阿霉素、顺铂）治疗胃癌４４例，其中术后辅助性化疗２０例，可评价疗效的有２４例。结果完全缓解２例，部分缓解１１例，总有效率５４．２％。中位生存期为６．５个月（３～３４个月）。化疗的主要不良反应为骨髓抑制及胃肠道反应。结果表明ＥＡＰ在现阶段仍是治疗晚期胃癌较为有效的方案，不良反应可以耐受
In order to observe the efficacy and adverse reactions of EAP regimen in the treatment of advanced gastric cancer, 44 patients with gastric cancer were treated with EAP (Acetochlor, Adriamycin or Epirubicin, and Cisplatin), of which 20 were postoperative adjuvant chemotherapy. There are 24 cases of curative effect. The results were complete remission in 2 cases, partial remission in 11 cases, and the total effective rate was 54.2%. The median survival time was 6.5 months (3 to 34 months). The major adverse reactions to chemotherapy are myelosuppression and gastrointestinal reactions. Results show that EAP is still a more effective treatment for advanced gastric cancer at this stage, and adverse reactions can be tolerated